Roundtable Roundup: Relapsed CLL After 2 Prior Lines
Fact checked by Dylann Cohn-Emery
Publication
Article
Peers & Perspectives in OncologyDecember II, 2024
Pages: 76
In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).
- CASE SUMMARY
- A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up.
- Medical history: type 2 diabetes controlled with insulin
- Patient received previous treatments with:
- First line: acalabrutinib (Calquence) monotherapy
- Achieved good clinical response over 3 years but later progressed on therapy
- Second line: venetoclax (Venclexta) plus rituximab (Rituxan)
- Completed 24-month treatment regimen
- Was in treatment-free interval for 6 months
- Due to disease progression, his hemoglobin has dropped over the past 3 months and is currently at 10 g/dL.
- At follow-up, the patient is now aged 70 years and does not report any symptoms yet.
- ECOG performance status: 0
Articles in this issue
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
Roundtable Roundup: Relapsed CLL After 2 Prior Lines
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
Managing Intermediate-Risk Myelofibrosis With Ruxolitinib
Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma
Brunner Discusses Dosing Approaches for ESA and Novel Therapies for Low-Risk MDS
Recent Videos
Related Content
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025Article
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
